Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Common Equity: 2020-2022

Historic Common Equity for Candel Therapeutics (CADL) over the last 3 years, with Dec 2022 value amounting to $47.7 million.

  • Candel Therapeutics' Common Equity fell 55.83% to $23.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $23.0 million, marking a year-over-year decrease of 55.83%. This contributed to the annual value of $47.7 million for FY2022, which is 25.61% down from last year.
  • Candel Therapeutics' Common Equity amounted to $47.7 million in FY2022, which was down 25.61% from $64.1 million recorded in FY2021.
  • Candel Therapeutics' 5-year Common Equity high stood at $64.1 million for FY2021, and its period low was -$23.6 million during FY2020.
  • Its 3-year average for Common Equity is $29.4 million, with a median of $47.7 million in 2022.
  • In the last 5 years, Candel Therapeutics' Common Equity skyrocketed by 372.21% in 2021 and then fell by 25.61% in 2022.
  • Over the past 3 years, Candel Therapeutics' Common Equity (Yearly) stood at -$23.6 million in 2020, then spiked by 372.21% to $64.1 million in 2021, then fell by 25.61% to $47.7 million in 2022.